GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Shiller PE Ratio

GeneThera (GeneThera) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GeneThera Shiller PE Ratio Historical Data

The historical data trend for GeneThera's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Shiller PE Ratio Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneThera's Shiller PE Ratio

For the Biotechnology subindustry, GeneThera's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GeneThera's Shiller PE Ratio falls into.



GeneThera Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GeneThera's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, GeneThera's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.004/125.2265*125.2265
=-0.004

Current CPI (Sep. 2022) = 125.2265.

GeneThera Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 -0.030 96.871 -0.039
201303 -0.010 98.209 -0.013
201306 -0.010 98.518 -0.013
201309 -0.010 98.790 -0.013
201312 -0.010 98.326 -0.013
201403 -0.010 99.695 -0.013
201406 -0.010 100.560 -0.012
201409 -0.004 100.428 -0.005
201412 0.000 99.070 0.000
201503 -0.010 99.621 -0.013
201506 -0.004 100.684 -0.005
201509 -0.010 100.392 -0.012
201512 -0.010 99.792 -0.013
201603 -0.010 100.470 -0.012
201606 -0.010 101.688 -0.012
201609 -0.010 101.861 -0.012
201612 0.000 101.863 0.000
201703 -0.010 102.862 -0.012
201706 -0.004 103.349 -0.005
201709 -0.004 104.136 -0.005
201712 0.000 104.011 0.000
201803 -0.010 105.290 -0.012
201806 -0.010 106.317 -0.012
201809 -0.010 106.507 -0.012
201812 -0.070 105.998 -0.083
201903 -0.004 107.251 -0.005
201906 -0.004 108.070 -0.005
201909 0.001 108.329 0.001
201912 0.000 108.420 0.000
202003 -0.004 108.902 -0.005
202006 -0.010 108.767 -0.012
202009 -0.010 109.815 -0.011
202012 -0.007 109.897 -0.008
202103 -0.010 111.754 -0.011
202106 -0.010 114.631 -0.011
202109 -0.010 115.734 -0.011
202112 -0.010 117.630 -0.011
202203 -0.004 121.301 -0.004
202206 -0.004 125.017 -0.004
202209 -0.004 125.227 -0.004

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GeneThera  (OTCPK:GTHR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GeneThera Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GeneThera's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines